The future of cancer treatment: Exploiting cancer’s key vulnerabilities
By Victoria Zazulina, M.D., head of development unit, oncology, for the healthcare business of Merck…
By Victoria Zazulina, M.D., head of development unit, oncology, for the healthcare business of Merck…
Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary…
Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan…
By 2026, pharma industry insiders anticipate cell and gene therapy sales to significantly increase, with…
Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a…
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial…
Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and…
An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen…
Sigma-Aldrich Co LLC, along with genOway, a preclinical research model space company, announced today (September…
Merck, also known as MSD outside the U.S. and Canada, and Orna Therapeutics, a biotech…
Immutep Limited, an Australian biotech company developing LAG-3-related immunotherapy treatments for cancer and autoimmune disease,…
BioMed X, a German independent research institute, has started a new research project ‘Extrachromosomal DNA…